The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Time to mammographic density decrease after exposure to tamoxifen
Magnus Bäcklund et al.

Supplemental Table 1. Inclusion and exclusion criteria.

INCLUSION CRITERIA To participate, the women must meet the following inclusion criteria:

- Participant of the Karma Cohort
- Attending the national mammography screening program, *i.e.* aged 40-74
- Mammogram 3 weeks before start of therapy
- Mammographic volumetric density >4%, measured by Volpara
- Informed consent signed before study specific assessments are performed

EXCLUSION CRITERIA To participate, the women must not meet any of the following exclusion criteria:

- Being pregnant or planning to become pregnant during the study
- Any previous or current diagnosis of breast cancer (including carcinoma in situ)
- Recalled (mammographic code 3 or above) after baseline screening mammography
- Any previous diagnosis of cancer, with the exception of non-melanoma skin cancer and *in situ* cancer of the cervix
- Currently using oestrogen and progesterone-based hormone replacement therapy
- Current use of hormone contraceptive with hormones, *e.g.* hormonal contraceptive pills, or progesterone implants. Hormonal intrauterine devices are accepted.
- A history of thromboembolic disease such as embolism, deep vein thrombosis, stroke, TIA or cardiac arrest.
- A history of immobilization, *e.g.* using wheelchair
- Known uncontrolled diabetes
- Hypertension at baseline, defined as systolic pressure higher than 140 mm Hg and diastolic higher than 90 mm Hg
- Use of drugs that interfere with CYP2D6 expression such as paroxetine, fluoxetine and bupropion